In one randomized phase III trial with stage IV or recurrent NSCLC, nivolumab as the first-line therapy was found not superior to chemotherapy in PFS among patients whose tumor had a PDL1 expression of ≥5%. Here, CD274 is linked to non-small cell lung carcinoma.